Basilea Pharmaceutica
BSLN.SWDrugs in Pipeline
17
Phase 3 Programs
11
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Fosmanogepix IV infusion
Invasive Mold Infections
ceftobiprole medocaril
Skin Diseases, Infectious
Vancomycin
Skin Diseases, Infectious
vancomycin+aztreonam
Acute Bacterial Skin and Skin Structure Infections
Fosmanogepix
Candidemia
IV standard-of-care cephalosporin
Community-acquired Pneumonia (CAP)
linezolid plus ceftazidime
Pneumonia
Ceftriaxone with or without Linezolid
Pneumonia
Isavuconazole
Acute Myeloid Leukemia
Daptomycin
Staphylococcus Aureus Bacteremia
alitretinoin
Hand Dermatoses
derazantinib
Intrahepatic Cholangiocarcinoma
Derazantinib 300 mg once daily monotherapy
Urothelial Carcinoma
Derazantinib low dose range
Solid Tumor
Lisavanbulin Phase 1 dose escalation portion
Neoplasms
APX001
Candidemia
BAL101553
Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fosmanogepix IV infusion | Phase 3 | Invasive Mold Infections | - | - |
ceftobiprole medocaril | Phase 3 | Skin Diseases, Infectious | - | - |
Vancomycin | Phase 3 | Skin Diseases, Infectious | - | - |
vancomycin+aztreonam | Phase 3 | Acute Bacterial Skin and Skin Structure Infections | - | - |
Fosmanogepix | Phase 3 | Candidemia | - | - |
IV standard-of-care cephalosporin | Phase 3 | Community-acquired Pneumonia (CAP) | - | - |
linezolid plus ceftazidime | Phase 3 | Pneumonia | - | - |
Ceftriaxone with or without Linezolid | Phase 3 | Pneumonia | - | - |
Isavuconazole | Phase 3 | Acute Myeloid Leukemia | - | - |
Daptomycin | Phase 3 | Staphylococcus Aureus Bacteremia | - | - |
alitretinoin | Phase 3 | Hand Dermatoses | - | - |
derazantinib | Phase 2 | Intrahepatic Cholangiocarcinoma | - | - |
Derazantinib 300 mg once daily monotherapy | Phase 2 | Urothelial Carcinoma | - | - |
Derazantinib low dose range | Phase 2 | Solid Tumor | - | - |
Lisavanbulin Phase 1 dose escalation portion | Phase 2 | Neoplasms | - | - |
APX001 | Phase 2 | Candidemia | - | - |
BAL101553 | Phase 2 | Neoplasms | - | - |
Frequently asked questions
What is in Basilea Pharmaceutica's drug pipeline?→
CatalystAlert tracks 17 drug candidates in Basilea Pharmaceutica's (BSLN.SW) pipeline across Phase 3, Phase 2. Its lead program is Fosmanogepix IV infusion (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Basilea Pharmaceutica's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Basilea Pharmaceutica (BSLN.SW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BSLN.SW biotech catalysts?→
Add BSLN.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Basilea Pharmaceutica's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.